Physician (internal medicine, immunology and allergy), trained at Geneva university Hospital, MDPhD at Unige (group pof Bernard Mach/Walter Reith), post doc at Massachusetts General Hospital, Harvard medical school (group of Megan Sykes). Currently head of the Plateforme des laboratoire de thérapies cellulaire et transplantation at HUG (chef de service, full professor at UNIGE).
I’m an expert in HLA leading during many years the laboratoire national de réference pour l’histocompatibilité, my research focus on hematopoietic stem cell transplantation (HSCT), by looking at immunogenetics factors such as HLA, KIR genes to fine-tuned the process to find the best suitable donor search to prevent relapse, GVH…after HSCT. At the national level I‘im member of several commission if the Swiss blood stem cell and Swisstransplant Foundation- At the international level I’m the treasurer of the European federation for immunogenetics I can contribute to the center with my expertise in immunogenetics (HLA, KIR), by providing access to cohort of patients (>2000) with clinical data and by my expertise in ATMP to help translation process for clinical use.

My research focus on the analysis of HLA loci typed at high resolution to improve access the choice of suitable donors in case of HSCT, we did significant work with DPB1 locus which was less study. We are working on the KIR genotyping though a novel approach to typed KIR at high resolution.

We are also currently working in collaboration with group of David Gfeller at UNIL on the potential importance of the immunopeptidome to stratify the risk of GVH. In parallel extensive TCR analysis have been performed to identify specific motif that be associated with clinical outcome such as graft versus host disease (GVH) or viral infecin(CMV). From experimental protocol on a small cohort of patients from whom we have access to biological material (cells, plama…), we then extend our hypothesis on a large cohort of patient after HSCT (>2000) with clinical data that have been collected over years. We have also international collaboration to have access to independent cohorts (France, US, GB).

By leading the laboratoire de therapie cellulaire at HUG (GMP lab), I have also an expertise in the accreditation processes, and in the work that has to be done to provide strong files to Swissmedic for ATMP developement into phase I/II cilnical studies.